hsa-miR-92b-5p高表达预测低级别胶质瘤放射抗拒的相关研究
The study about low-grade glioma radioresistance prediction based on the high hsa-miR-92b-5p expression
何璐 1郭伟盛 1闫冰川2
作者信息
- 1. 广州医科大学附属肿瘤医院放疗科,广州 510095
- 2. 广州医科大学附属肿瘤医院中西医结合二科,广州 510095
- 折叠
摘要
探讨hsa-miR-92b-5p表达水平对低级别胶质瘤患者肿瘤放射敏感性的预测价值.在接受放射治疗的低级别胶质瘤患者中肿瘤组织hsa-miR-92b-5p高表达患者总体生存[5年生存率:(45.8± 5.9)％比(64.1±6.9)％;P＜0.001]与无进展生存[5年无进展生存率:(24.1±5.5)％比(56.6±6.6)％;P＜0.001]均显著低于hsa-miR-92b-5p低表达患者.说明hsa-miR-92b-5p高表达提示低级别胶质瘤放射抗拒,其在指导低级别胶质瘤个体化治疗方面具有潜在的临床应用价值.
Abstract
To investigate the predictive value of hsa-miR-92b-5p expression for radiosensitivity in patients with low-grade glioma.For low-grade glioma patients received radiotherapy,the overall survival and the progression-free survival of the patients with high hsa-miR-92b-5p expression was significantly lower than that of the patients with low hsa-miR-92b-5p expression[5-year survival rate:(45.8±5.9)％vs(64.1± 6.9)％,P＜0.001;5-year progression-free survival rate:(24.1±5.5)％vs(56.6±6.6)％,P＜0.001].The high expression of hsa-miR-92b-5p suggested radioresistance of low-grade glioma.The expression of hsa-miR-92b-5p had potential to be a radioresistance biomarker to guide the individualized treatment of low-grade glioma.
关键词
胶质瘤/微RNA/预后/放射敏感性/分子标志物Key words
Glioma/miRNA/Prognosis/Radiosensitivity/Molecular marker引用本文复制引用
出版年
2023
NETL
NSTL
万方数据